Globelmmune (GBIM) up 38% on Upcoming Drug News

Stephen L Kanaval  |

Globelmmune Inc. (GBIM) fights disease in a way that can only be described as inexplicable. The unusual method involves a heat-inactivated yeast containing Tarmogen, which if all goes well reduces target cells that also contain Tarmogen. Undoubtedly, the most interesting aspect of collaborations with Gilead (GILD) and Celgene (CELG) and for a company valued at $12m as of mid-June 2016, the potential profits of the partnerships are strong.

Regarding Celene, the company will award GlobeImmune up to $85m for its GI-6100 program currently in pre-clinical testing with full development costs to be borne by CELG. An additional $60m will be awarded to GBIM if the GI-6200 program reaches full development, currently in Phase 2. Plus, another $85 if the GI-6300 program has success, which is currently in phase 1 and 2.

Regarding Gilead, the GS-4774 clinical trial phase 2 results are coming soon and the additional phase 2 study for the GI-6301 medullary thyroid cancer treatment are also expected soon.

The lack of verifiable data along with the stock moving up 38% at the time of writing probably means that good news is coming soon.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
GBIM GlobeImmune Inc. 0.10 0.00 0.00 0



Symbol Last Price Change % Change






What Is Petrolithium?

MGX Minerals explains the advantages of petrolithium and how they are helping to solve future problems today.